<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; MTXX</title>
	<atom:link href="http://www.stockbloghub.com/tag/mtxx/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MTXX) Matrixx Initiatives Inc. &#8211; Aggressive Growth &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/04/16/mtxx-matrixx-initiatives-inc-aggressive-growth-zacks-rank-buy/5607</link>
		<comments>http://www.stockbloghub.com/2009/04/16/mtxx-matrixx-initiatives-inc-aggressive-growth-zacks-rank-buy/5607#comments</comments>
		<pubDate>Thu, 16 Apr 2009 21:46:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Matrixx Initiatives Inc.]]></category>
		<category><![CDATA[MTXX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=5607</guid>
		<description><![CDATA[Matrixx Initiatives, Inc. (MTXX) blew away analyst estimates, driven by strong organic sales growth for its fourth consecutive earnings surprise. Company Description Matrixx Initiatives, Inc. is a nutrient and drug delivery technology company engaged in the development, manufacture and marketing of delivery systems for bioactive compounds. Gel Tech, LLC, its wholly-owned subsidiary, produces, markets and sells over-the-counter treatments under the Zicam name. Sales up 26% In the latest earnings announcement, on Jan 26, Matrixx reported earnings per share of 50 cents. The consensus was just 31 cents making it a 61% and fourth consecutive surprise. Matrixx posted a 7 cent loss in the third-quarter of last year. A 26% spike in sales was the main driver behind the excellent quarter, specifically the company&#8217;s Cold Remedy swabs and new Allergy swabs. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/04/16/mtxx-matrixx-initiatives-inc-aggressive-growth-zacks-rank-buy/5607/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MTXX) Matrix Initiatives, Inc. &#8211; Value &#8211; Zacks Rank Buy</title>
		<link>http://www.stockbloghub.com/2009/03/10/mtxx-matrix-initiatives-inc-value-zacks-rank-buy/4161</link>
		<comments>http://www.stockbloghub.com/2009/03/10/mtxx-matrix-initiatives-inc-value-zacks-rank-buy/4161#comments</comments>
		<pubDate>Tue, 10 Mar 2009 17:54:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Matrixx Initiatives Inc.]]></category>
		<category><![CDATA[MTXX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=4161</guid>
		<description><![CDATA[Matrix Initiatives Inc. (MTXX) is cashing in on over-the-counter cough and cold products as revenue rose 26% in the fiscal third quarter. The company has surprised on estimates 4 consecutive quarters by an average of 28.48%. MTXX has a PEG ratio of only 0.9. Company Description Matrix Initiatives manufactures over-the-counter healthcare products that use unique drug delivery systems. The company&#8217;s wholly-owned subsidiary, Zicam LLC, sells Zicam and Nasal Comfort products in the cough and cold segment and Xcid antacid in the digestive health category. Matrix&#8217;s premiere product is the Zicam Cold Remedy nasal gel, which the company says has been clinically proven to reduce the duration and severity of the common cold. Revenue Jumped 26% in the Third Quarter 2009 On Jan 26, the company reported third quarter earnings that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/03/10/mtxx-matrix-initiatives-inc-value-zacks-rank-buy/4161/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MTXX) Matrixx Initiatives &#8211; fourth time in the last four quarters that Matrixx has beat estimates</title>
		<link>http://www.stockbloghub.com/2009/02/17/mtxx-matrixx-initiatives-fourth-time-in-the-last-four-quarters-that-matrixx-has-beat-estimates/2727</link>
		<comments>http://www.stockbloghub.com/2009/02/17/mtxx-matrixx-initiatives-fourth-time-in-the-last-four-quarters-that-matrixx-has-beat-estimates/2727#comments</comments>
		<pubDate>Tue, 17 Feb 2009 23:01:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Matrixx Initiatives Inc.]]></category>
		<category><![CDATA[MTXX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=2727</guid>
		<description><![CDATA[Matrixx Initiatives, Inc. (MTXX) posted impressive third-quarter results in late January, sending its share price above its 6-month high. Third-Quarter Results Matrixx Initiatives is fresh off the heels of solid third-quarter results, reported on Jan 26, that were ahead of expectations. Revenue was up 26% from last year to $38.7 million. Net income spiked higher, jumping to $4.8 million from a loss of $635,000 in the same period last year. This produced earnings of 50 cents per share, far ahead of the consensus estimate of 31 cents. Consistent Results This was the fourth time in the last four quarters that Matrixx has beat estimates, having done so by an average of 11 cents, or 28%. Analyst Estimates The analyst community is bullish on Matrixx, with the current-year estimate up 12 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/02/17/mtxx-matrixx-initiatives-fourth-time-in-the-last-four-quarters-that-matrixx-has-beat-estimates/2727/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MTXX) Matrixx Initiatives, Inc &#8211; Analyst estimates have continued to tick higher</title>
		<link>http://www.stockbloghub.com/2008/11/13/mtxx-matrixx-initiatives-inc-analyst-estimates-have-continued-to-tick-higher/1352</link>
		<comments>http://www.stockbloghub.com/2008/11/13/mtxx-matrixx-initiatives-inc-analyst-estimates-have-continued-to-tick-higher/1352#comments</comments>
		<pubDate>Thu, 13 Nov 2008 18:27:16 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[MTXX]]></category>
		<category><![CDATA[VitalStocks]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=1352</guid>
		<description><![CDATA[Matrixx Initiatives, Inc. (MTXX) is fresh off the heels of another strong quarter, reporting results that easily eclipsed analyst estimates. The company has more than doubled its cash holdings in the last year and has no debt. Company Description Matrixx Initiatives, Inc., through its subsidiaries develops and manufactures over-the-counter healthcare products. The company&#8217;s products include nasal sprays, cold medicines and vitamin products. Matrixx was founded in 1991 and has a market cap of $169 million. Industry Trend The healthcare sector has been able to weather the economic storm much better than many other industries, supported by less elastic demand for goods and services. This dynamic was evident when Matrixx reported great second-quarter results on Oct 22. Second-Quarter Results Revenue was up 18% to $33.6 million. Net income totaled $8.2 million, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2008/11/13/mtxx-matrixx-initiatives-inc-analyst-estimates-have-continued-to-tick-higher/1352/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

